Tirzepatide — Complete Research Guide (2026)
Last updated 2026-06-25
TL;DR
A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and weight management (Zepbound), with large phase-3 trial programs.
What is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist — it activates two incretin pathways at once. It is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management).
Its molecular formula is C225H348N48O68 and its plasma half-life is roughly 5 days, supporting once-weekly subcutaneous dosing.
Like semaglutide, tirzepatide is supported by a large phase-3 trial program, so the claims below rest on randomized controlled evidence rather than anecdote.
How does Tirzepatide work?
By co-agonising the GIP and GLP-1 receptors, tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite. The dual-incretin mechanism is associated with larger average weight reductions than single GLP-1 agonism in head-to-head data.
[INFOGRAPHIC: Dual GIP/GLP-1 receptor co-agonism]
What does the research say about Tirzepatide?
- In SURMOUNT-1 (n=2,539), tirzepatide produced mean weight reductions of 15.0% (5 mg), 19.5% (10 mg) and 20.9% (15 mg) versus 3.1% with placebo at 72 weeks. [1]
- In the SURPASS-2 head-to-head RCT (n=1,879), tirzepatide produced greater HbA1c and body-weight reductions than semaglutide 1 mg across all three doses. [2]
- In SURMOUNT-2, in adults with type 2 diabetes and obesity, tirzepatide produced clinically significant weight loss versus placebo. [3]
Clinical research & studies
The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.
- [1] Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — Jastreboff AM et al., N Engl J Med 2022. (phase-3 RCT, n=2,539)
- [2] Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) — Frías JP et al., N Engl J Med 2021. (phase-3 open-label RCT, n=1,879)
- [3] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — Garvey WT et al., Lancet 2023. (phase-3 RCT)
- [4] Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes (SURPASS-6) — Rosenstock J et al., JAMA 2023. (phase-3 RCT)
- [5] Tirzepatide reduces the predicted risk of developing type 2 diabetes: post-hoc analysis of SURMOUNT-1 — Jastreboff AM et al., Diabetes Care 2023. (post-hoc analysis of RCT)
Dosing context
Approved use follows a stepwise dose-escalation schedule, reported here only as published research context, not instruction.
This is not medical advice or a usage recommendation. Tirzepatide is a prescription medicine to be used only under a licensed prescriber.
Side effects & safety profile
As with other incretin agents, the most common adverse effects are gastrointestinal — nausea, diarrhoea and vomiting — predominantly during dose escalation.
Approved labels include a boxed warning regarding thyroid C-cell tumors seen in rodents, with contraindications in medullary thyroid carcinoma or MEN 2 history.
These data describe the approved products under medical supervision; unregulated research-labelled material is not covered by this evidence.
Stacking & combinations
The most relevant comparison is with semaglutide (SURPASS-2). There is no evidence supporting combining tirzepatide with other incretin agents outside a clinical trial.
Finding Tirzepatide vendors
Finding Tirzepatide vendors
This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.
Choose your country
We never list placeholder vendors. Pick your country to see neutral regulatory context.
User reviews
No reviews yet
Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.
Frequently asked questions
Tirzepatide activates two incretin receptors (GIP and GLP-1); semaglutide activates one (GLP-1). In SURPASS-2 head-to-head, tirzepatide produced greater HbA1c and weight reductions.
References
- [1] Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — Jastreboff AM et al., N Engl J Med 2022. PMID: 35658024. View sourceStudy: phase-3 RCT, n=2,539Mean weight reduction up to 20.9% (15 mg) vs 3.1% placebo at 72 weeks.
- [2] Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2) — Frías JP et al., N Engl J Med 2021. PMID: 34170647. View sourceStudy: phase-3 open-label RCT, n=1,879Greater HbA1c and weight reduction than semaglutide 1 mg across all doses.
- [3] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — Garvey WT et al., Lancet 2023. PMID: 37385275. View sourceStudy: phase-3 RCTClinically significant weight loss vs placebo in adults with T2D and obesity.
- [4] Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes (SURPASS-6) — Rosenstock J et al., JAMA 2023. PMID: 37786396. View sourceStudy: phase-3 RCTCompared tirzepatide to prandial insulin lispro added to basal insulin.
- [5] Tirzepatide reduces the predicted risk of developing type 2 diabetes: post-hoc analysis of SURMOUNT-1 — Jastreboff AM et al., Diabetes Care 2023. PMID: 37700443. View sourceStudy: post-hoc analysis of RCTSignificantly lowered 10-year predicted T2D risk vs placebo regardless of baseline glycemia.